RxDoctor Payments Data

James Trippett, MD

Family Medicine · Sugar Land, TXNPI 1366473894

Payments from drug & device makers

$17,648in general payments, 2019–2025

Across 900 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Abbott$2K
  • Amgen$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$1K
  • AbbVie$943
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$17,615100%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk90$2,039
Abbott141$1,731
Amgen(2 entities)64$1,288
Lilly USA, LLC46$1,113
Boehringer Ingelheim37$1,045
AbbVie(2 entities)59$943
AstraZeneca39$902
Optinose US, Inc.21$657
Bayer19$628
Teva Pharmaceuticals USA, Inc.18$587
GSK29$548
Pfizer34$512
Amarin Pharma, Inc.38$489
Johnson & Johnson25$445
Merck29$398
Renalytix AI, Inc.8$259
Sanofi-aventis U.S. LLC12$249
Corcept Therapeutics7$246
Inspire Medical Systems, Inc.6$244
Astellas Pharma US Inc13$242
Takeda Pharmaceuticals U.S.A., Inc.14$237
Eisai Inc.18$236
Dexcom, Inc.12$227
Amneal Pharmaceuticals LLC8$189
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$178
ARS Pharmaceuticals Operations, Inc.3$177
Sumitomo Pharma America, Inc.9$154
Shield Therapeutics Inc8$139
Exact Sciences8$128
Esperion Therapeutics, Inc.6$115
Saluda Medical Americas, Inc.2$115
Mannkind Corporation2$110
Biohaven Pharmaceuticals, Inc.6$99
Sanofi Pasteur Inc.5$87
Biohaven Pharmaceutical Holding Company Ltd.5$76
Intuitive Surgical1$73
Radius Health, Inc.5$66
Shire North American Group Inc4$60
Genentech USA, Inc.3$47
Ironshore Pharmaceuticals Inc.3$41
Seqirus USA Inc2$40
Antares Pharma, Inc.2$31
Verity Pharmaceuticals Inc.2$31
Corium, LLC2$30
Phathom Pharmaceuticals, Inc.1$26
Aerin Medical Inc.1$25
Azurity Pharmaceuticals, Inc.1$24
Avvisto Therapeutics, LLC1$22
Dynavax Technologies Corporation1$21
Medtronic1$20
Viatris Specialty LLC1$20
Bausch Health US, LLC1$20
Axsome Therapeutics, Inc.1$19
Currax Pharmaceuticals LLC1$18
Clarus Therapeutics Inc.1$17
Mylan Specialty L.p.1$16
Novartis1$16
Neos Therapeutics, LP1$15
Dermira, Inc.1$15
Acerus Pharmaceuticals Corporation1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,648 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$88,506
Medicare patients
377
Services billed
2,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide162$196,459
MounjaroTirzepatide40$44,934
TrulicityDulaglutide27$38,678
JardianceEmpagliflozin25$35,514
FarxigaDapagliflozin Propanediol29$35,243
EliquisApixaban29$35,088
VascepaIcosapent Ethyl20$18,128
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,781
RybelsusSemaglutide15$15,738
Tresiba Flextouch U-200Insulin Degludec14$10,435
Lagevrio (Eua)Molnupiravir12$8,555
Atorvastatin Calcium620$6,503
Levothyroxine Sodium437$5,216
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,193
Losartan Potassium242$2,663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,039$212,198177 claims
Lilly USA, LLCMounjaro, Trulicity$1,113$83,61367 claims
PfizerEliquis, Paxlovid$512$36,51754 claims
Boehringer IngelheimJardiance$1,045$35,51425 claims
AstraZenecaFarxiga$902$35,24329 claims
GSKTrelegy Ellipta$548$17,78127 claims
MerckLagevrio (Eua)$398$8,55512 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$189$5,216437 claims
AbbVieSynthroid$943$1,77634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →